Do analysts rate RGC or CYRX?

CryoPort has a consensus target price of $18.00, indicating a potential upside of 21.29%. Given CryoPort's stronger consensus rating and higher probable upside, analysts clearly believe CryoPort is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CryoPort 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has higher valuation & earnings, RGC or CYRX?

CryoPort has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A CryoPort $176.18M 4.27 $78.30M -$0.90 N/A

Does the media favor MBX or CYRX?

In the previous week, CryoPort had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 14 mentions for CryoPort and 10 mentions for MBX Biosciences. CryoPort's average media sentiment score of 0.27 beat MBX Biosciences' score of 0.07 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer CYRX or MOR?

CryoPort currently has a consensus target price of $18.00, suggesting a potential upside of 21.29%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, CYRX or MOR?

CryoPort has higher earnings, but lower revenue than MorphoSys. CryoPort is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.27 $78.30M -$0.90 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is CYRX or MOR more profitable?

CryoPort has a net margin of -20.05% compared to MorphoSys' net margin of -226.79%. CryoPort's return on equity of -7.20% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% MorphoSys -226.79% -694.31% -22.55%

Is CYRX or IRON more profitable?

Disc Medicine has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% Disc Medicine N/A -37.17% -33.65%

Does the media favor CYRX or IRON?

In the previous week, Disc Medicine had 9 more articles in the media than CryoPort. MarketBeat recorded 23 mentions for Disc Medicine and 14 mentions for CryoPort. Disc Medicine's average media sentiment score of 0.40 beat CryoPort's score of 0.27 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, BEAM or CYRX?

CryoPort has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beam Therapeutics $139.74M 20.20 -$79.99M -$0.86 N/A CryoPort $176.18M 4.27 $78.30M -$0.90 N/A

Does the media prefer BEAM or CYRX?

In the previous week, CryoPort had 4 more articles in the media than Beam Therapeutics. MarketBeat recorded 14 mentions for CryoPort and 10 mentions for Beam Therapeutics. CryoPort's average media sentiment score of 0.27 beat Beam Therapeutics' score of -0.13 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral CryoPort 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

CryoPort (CYRX) Competitors

$14.84 -0.28 (-1.85%)

As of 03:57 PM Eastern

Compare

CYRX vs. RGC, MBX, MOR, IRON, and BEAM

Should you buy CryoPort stock or one of its competitors? MarketBeat compares CryoPort with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CryoPort include Regencell Bioscience (RGC), MBX Biosciences (MBX), MorphoSys (MOR), Disc Medicine (IRON), and Beam Therapeutics (BEAM).

How does CryoPort compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and CryoPort (NASDAQ:CYRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, CryoPort had 14 more articles in the media than Regencell Bioscience. MarketBeat recorded 14 mentions for CryoPort and 0 mentions for Regencell Bioscience. CryoPort's average media sentiment score of 0.27 beat Regencell Bioscience's score of 0.00 indicating that CryoPort is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
CryoPort	Neutral

CryoPort has a consensus target price of $18.00, indicating a potential upside of 21.29%. Given CryoPort's stronger consensus rating and higher probable upside, analysts clearly believe CryoPort is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Regencell Bioscience has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. Regencell Bioscience's return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
CryoPort	-20.05%	-7.20%	-4.30%

Regencell Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

CryoPort has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
CryoPort	$176.18M	4.27	$78.30M	-$0.90	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

CryoPort beats Regencell Bioscience on 10 of the 13 factors compared between the two stocks.

How does CryoPort compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and CryoPort (NASDAQ:CYRX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

In the previous week, CryoPort had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 14 mentions for CryoPort and 10 mentions for MBX Biosciences. CryoPort's average media sentiment score of 0.27 beat MBX Biosciences' score of 0.07 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CryoPort has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
CryoPort	$176.18M	4.27	$78.30M	-$0.90	N/A

92.9% of CryoPort shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Comparatively, 9.5% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MBX Biosciences presently has a consensus price target of $75.63, suggesting a potential upside of 14.91%. CryoPort has a consensus price target of $18.00, suggesting a potential upside of 21.29%. Given CryoPort's stronger consensus rating and higher probable upside, analysts plainly believe CryoPort is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

MBX Biosciences has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
CryoPort	-20.05%	-7.20%	-4.30%

MBX Biosciences has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

Summary

CryoPort beats MBX Biosciences on 12 of the 16 factors compared between the two stocks.

How does CryoPort compare to MorphoSys?

CryoPort (NASDAQ:CYRX) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

CryoPort has higher earnings, but lower revenue than MorphoSys. CryoPort is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.27	$78.30M	-$0.90	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

In the previous week, CryoPort had 14 more articles in the media than MorphoSys. MarketBeat recorded 14 mentions for CryoPort and 0 mentions for MorphoSys. CryoPort's average media sentiment score of 0.27 beat MorphoSys' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company	Overall Sentiment
CryoPort	Neutral
MorphoSys	Neutral

CryoPort has a net margin of -20.05% compared to MorphoSys' net margin of -226.79%. CryoPort's return on equity of -7.20% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
MorphoSys	-226.79%	-694.31%	-22.55%

92.9% of CryoPort shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 9.5% of CryoPort shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CryoPort currently has a consensus target price of $18.00, suggesting a potential upside of 21.29%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CryoPort beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does CryoPort compare to Disc Medicine?

CryoPort (NASDAQ:CYRX) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

92.9% of CryoPort shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Disc Medicine. CryoPort is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.27	$78.30M	-$0.90	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

In the previous week, Disc Medicine had 9 more articles in the media than CryoPort. MarketBeat recorded 23 mentions for Disc Medicine and 14 mentions for CryoPort. Disc Medicine's average media sentiment score of 0.40 beat CryoPort's score of 0.27 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort currently has a consensus price target of $18.00, suggesting a potential upside of 21.29%. Disc Medicine has a consensus price target of $106.00, suggesting a potential upside of 35.41%. Given Disc Medicine's higher probable upside, analysts plainly believe Disc Medicine is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Disc Medicine has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Disc Medicine	N/A	-37.17%	-33.65%

Summary

CryoPort beats Disc Medicine on 9 of the 15 factors compared between the two stocks.

How does CryoPort compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CryoPort (NASDAQ:CYRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Beam Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

In the previous week, CryoPort had 4 more articles in the media than Beam Therapeutics. MarketBeat recorded 14 mentions for CryoPort and 10 mentions for Beam Therapeutics. CryoPort's average media sentiment score of 0.27 beat Beam Therapeutics' score of -0.13 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
CryoPort	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CryoPort has a net margin of -20.05% compared to Beam Therapeutics' net margin of -54.75%. CryoPort's return on equity of -7.20% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
CryoPort	-20.05%	-7.20%	-4.30%

CryoPort has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	20.20	-$79.99M	-$0.86	N/A
CryoPort	$176.18M	4.27	$78.30M	-$0.90	N/A

Beam Therapeutics currently has a consensus target price of $49.00, suggesting a potential upside of 79.29%. CryoPort has a consensus target price of $18.00, suggesting a potential upside of 21.29%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 9.5% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CryoPort beats Beam Therapeutics on 10 of the 16 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$751.65M	$9.57B	$7.05B	$12.94B
Dividend Yield	N/A	1.45%	2.58%	10.20%
P/E Ratio	-16.49	62.59	269.76	24.76
Price / Sales	4.27	104.75	651.81	108.50
Price / Cash	N/A	26.16	28.89	37.44
Price / Book	1.61	5.15	11.28	6.42
Net Income	$78.30M	$56.66B	$3.45B	$347.27M
7 Day Performance	-4.20%	3.61%	3.61%	2.52%
1 Month Performance	-8.23%	0.57%	-0.53%	-1.00%
1 Year Performance	96.30%	24.02%	77.55%	23.29%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	3.1262 of 5 stars	$14.84 -1.9%	$18.00 +21.3%	+100.0%	$751.65M	$176.18M	N/A	1,186	Earnings Report Analyst Forecast
RGC Regencell Bioscience	0.1528 of 5 stars	$5.65 -5.4%	N/A	-61.3%	$2.95B	N/A	N/A	10	Gap Up
MBX MBX Biosciences	1.9826 of 5 stars	$63.96 +6.5%	$71.13 +11.2%	N/A	$2.86B	N/A	N/A	N/A	Earnings Report Analyst Forecast
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
IRON Disc Medicine	2.2235 of 5 stars	$73.67 -1.3%	$104.44 +41.8%	+33.4%	$2.85B	N/A	N/A	30	Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. RGC, MBX, MOR, IRON, and BEAM

How does CryoPort compare to Regencell Bioscience?

Summary

How does CryoPort compare to MBX Biosciences?

Summary

How does CryoPort compare to MorphoSys?

Summary

How does CryoPort compare to Disc Medicine?

Summary

How does CryoPort compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. RGC, MBX, MOR, IRON, and BEAM

How does CryoPort compare to Regencell Bioscience?

Does the media refer more to RGC or CYRX?

Do analysts rate RGC or CYRX?

Is RGC or CYRX more profitable?

Which has more volatility and risk, RGC or CYRX?

Which has higher valuation & earnings, RGC or CYRX?

Do insiders and institutionals believe in RGC or CYRX?

Summary

How does CryoPort compare to MBX Biosciences?

Does the media favor MBX or CYRX?

Which has preferable earnings and valuation, MBX or CYRX?

Do insiders and institutionals hold more shares of MBX or CYRX?

Do analysts prefer MBX or CYRX?

Is MBX or CYRX more profitable?

Which has more risk and volatility, MBX or CYRX?

Summary

How does CryoPort compare to MorphoSys?

Which has more volatility & risk, CYRX or MOR?

Which has stronger valuation & earnings, CYRX or MOR?

Does the media prefer CYRX or MOR?

Is CYRX or MOR more profitable?

Do insiders & institutionals hold more shares of CYRX or MOR?

Do analysts prefer CYRX or MOR?

Summary

How does CryoPort compare to Disc Medicine?

Which has more risk & volatility, CYRX or IRON?

Do institutionals and insiders believe in CYRX or IRON?

Which has higher earnings and valuation, CYRX or IRON?

Does the media favor CYRX or IRON?

Do analysts rate CYRX or IRON?

Is CYRX or IRON more profitable?

Summary

How does CryoPort compare to Beam Therapeutics?

Which has more risk and volatility, BEAM or CYRX?

Does the media prefer BEAM or CYRX?

Is BEAM or CYRX more profitable?

Which has higher earnings and valuation, BEAM or CYRX?

Do analysts rate BEAM or CYRX?

Do institutionals & insiders hold more shares of BEAM or CYRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools